Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
Eli Lilly is building a $4.5 billion factory to speed up drug production
Pharmaceutical giant Eli Lilly (LLY) is putting $4.5 billion toward building a new site to develop and manufacture drugs.
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
US FDA says Lilly's weight-loss drug no longer in shortage
Eli Lilly's blockbuster weight-loss drug is no longer in shortage in the United States, the U.S. Food and Drug Administration's website showed on Wednesday. The shortage of all doses of the drug, tirzepatide,
How long can Eli Lilly ride the weight-loss drug boom?
The company is set to become the first $1tn drugmaker, but investors see warning signs it has reached ‘peak enthusiasm’
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when
Eli Lilly considers testing weight-loss drugs on people who are not overweight
Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight gain, in an early sign that the drugmaker may look to broaden the rollout of the medications beyond obese patients.
Eli Lilly (NYSE:LLY) Eyes Broader Market for Weight-Loss Drugs
Eli Lilly ($LLY) is considering testing its blockbuster weight-loss drugs in individuals who are not yet overweight but are at risk of weight
Lilly to invest $4.5 bln on new facility to scale-up pipeline drug production
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and ...
Lilly Shells Out $4.5 Billion for New Drug Development Plant
Eli Lilly & Co. is pouring $4.5 billion into a new manufacturing plant in Indiana to make drugs for future clinical trials, ...
Drugmaker Lilly slates another $4.5B for manufacturing and drug development improvements
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
Eli Lilly to build $4.5 billion Indiana facility for advanced drug manufacturing
Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...
Lilly plans $4.5B ‘foundry’ for advanced drug manufacturing
The latest investment in the Lebanon site comes after an announcement in May of $5.3 billion earmarked to build production ...
STAT19h
Lilly invests $4.5 billion in a new research hub
Eli Lilly will invest $4.5 billion to create the Lilly Medicine Foundry, which the drug giant says will be the first-ever ...
Lilly looking to test Zepbound as health maintenance drug: report
Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
Eli Lilly announces a $4.5B investment to build the Lilly Medicine Foundry, a state-of-the-art facility in Indiana. The new ...
Eli Lilly plans $4.5 billion facility in LEAP District, bringing investment to $13 billion
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...